You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB
SBC: CELLF-BIO LLC Topic: 300Project Summary/Abstract:Fecal incontinence (FI), the involuntary soiling of various amounts of liquid and solid stool, is often devastating from a social, psychological, and hygiene perspective. Men and women suffer from FI equally with a range of 2 - 6% in people aged 20 - 30 years. The prevalence increases to over 15% in people older than 70 years1. FI may result from an isolated or combined lo ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast
SBC: CELDARA MEDICAL, LLC Topic: 500Project Summary This project describes the formation, launch and operation of the DRIVEN Accelerator Hub, with the express goal of reducing morbidity and mortality by increasing the number of medical entrepreneurs and their level of competency. The Hub is focused on the Northeast and, in collaboration with similar Hubs, will contribute nationwide. It will, in a facile, complete, and accessible way ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
SBC: BIOKIER, INC. Topic: 200SUMMARY Glucose homeostasis and food intake are both regulated by gut hormones secreted from enteroendocrine L- cells in the lower gut following stimulation by nutrients. This process is impaired in diabetes but is restored with delivery of dietary nutrients such as amino acids and fatty acids to the lower gut, such as after gastric bypass surgery and during fermentation of carbohydrates in the co ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
SBC: Nirvana Sciences, Inc. Topic: NIAIDAbstract Polychromatic flow cytometry (FC) is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells. Dyes used for FC typically exhibit broad fluorescent emission bands with full-width-at-half-maximum (fwhm) values of 50–80 nm. This limits the maximum number of dyes, and thus the nu ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting leukocyte metabolism to treat human autoimmune disease
SBC: Immunext, Inc. Topic: RImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient transporter SLC16A1 (MCT1) is a multi-pass transmembrane protein responsible for the facilitated transport of critical metabolites, including products of glycolysis: lactate, pyruvate and ketones. Our strong preliminary data support ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a New Carbohydrate-based Anticoagulant Drug
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: NHLBILow molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
CometChip: Development of a high throughput DNA damage assay in hepatocytes
SBC: INTEGRATED LABORATORY SYSTEMS, LLC Topic: NIEHSAn estimated 10,000 animals are used in toxicology safety assessments to meet all regulatory requirements with testing spanning 5 to 10 yrs and exceeding $10 million dollars. There is a critical need to reduce reliance on animal testing and to develop highly predictive human-based biological models for safety assessments. Replacement of traditional animal toxicity tests for toxicology safety asses ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Point-of-care device to identify patients at risk for preeclampsia
SBC: AFFINERGY, LLC Topic: NAlthough international trends for maternal mortality have shown an overall decline, maternal mortality rates in the United States have increased by andgt;25% since 2000. One of the leading causes for this increase is preeclampsia, a complication of pregnancy characterized by elevated blood pressure, proteinuria, and endothelial dysfunction involving multiple organ systems. Worldwide, preeclampsia ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel assay to monitor Tacrolimus levels at the point of care
SBC: AFFINERGY, LLC Topic: NIAIDSUMMARY/ABSTRACT In 2016, over 33,000 organ transplants were performed in the United States, an increase of 20% over the past 5 years. Organ transplantation requires lifelong immunosuppression to prevent rejection of the transplant. Tacrolimus, a macrolide antibiotic, is one of the most effective immunosuppressants, with andgt;90% of solid organ transplant recipients receiving it as part of their ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Administrative Supplement for the Evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer
SBC: CIVATECH ONCOLOGY INC Topic: NCIParent Award: R44CA217587 Clinical Evaluation of the novel, Uni-directional Pd-103 CivaSheet for Lung Cancers CivaTech Oncology’s mission is to provide improved radiation therapy directly to localized tumors. The Company has developed a novel, polymer-encapsulated, membrane-like radiation source that emits radiation on only one side of the device – CivaSheet®. This directional source is compa ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health